<DOC>
	<DOCNO>NCT00816023</DOCNO>
	<brief_summary>The purpose study assess efficacy identify optimal dose ( ) ecallantide reduce blood loss subject undergoing coronary artery bypass surgery include use cardio pulmonary bypass .</brief_summary>
	<brief_title>A Dose-ranging Safety Efficacy Study Ecallantide Reduce Surgical Blood Loss Volume</brief_title>
	<detailed_description />
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<criteria>Written inform consent ( study subject appropriate legal representative ) prior studyrelated procedure part normal medical care Planned primary CABG surgery include use cardiopulmonary bypass . Planned concomitant surgery include ASD repair , valve replacement , carotid endarterectomy , CABG combine procedure repeat sternotomy ; Body weight &lt; 55 kg ; Planned hypothermia ( &lt; 28ÂºC ) ; Planned transfusion perioperative postoperative period ; Planned transfusion preoperatively donate autologous blood ; Female subject pregnant lactating ; Planned use desmopressin , lysine analog , atrial natriuretic hormone recombinant activate Factor VII ; Planned use corticosteroid pump prime solution ; Ejection fraction &lt; 30 % within 90 day prior surgery ; Evidence myocardial infarction within 5 day prior surgery ; History stroke transient ischemic attack within 3 month prior surgery ; Hypotension heart failure require use inotropes mechanical device within 24 hour prior surgery ; Serum creatinine &gt; 2.0 mg/dL within 48 hour prior surgery ; Serum hepatic enzymes 2.5 time upper limit normal applicable laboratory ; Hematocrit &lt; 32 % within 48 hour prior surgery ; Platelet count normal range applicable laboratory within 14 day prior surgery ; History , family history , bleed clot disorder thrombophilia ; History heparininduced thrombocytopenia ; Prothrombin time and/or activate partial thromboplastin time &gt; 1.5 X normal range ; Serious intercurrent illness active infection ; Any previous exposure ecallantide ; Receipt investigational drug device 30 day prior participation current study ; Known allergy agent expect used intraoperative postoperative period ; Administration : Eptifibatide within 6 hour prior surgery , Tirofiban HCl within 6 hour prior surgery , *Enoxaparin sodium lowmolecularweight heparin &lt; 24 hour prior surgery , Clopidogrel within 5 day prior surgery , Ticlopidine within 7 day prior surgery , Abciximab within 5 day prior surgery , *Bivalirudin , argatroban lepirudin within 6 hour prior surgery , *Fondaparinux within 72 hour prior surgery , Prasugrel within 10 day prior surgery [ *Prophylactic use permit prevention deep vein thrombosis . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>